Holen Sie sich die Stockscreener-App
2.12
4.43%
0.09
Handel nachbörslich:
2.11
-0.01
-0.47%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SAVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$2.03
Offen:
$2.03
24-Stunden-Volumen:
846.53K
Relative Volume:
0.80
Marktkapitalisierung:
$102.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.22M
KGV:
-1.5362
EPS:
-1.38
Netto-Cashflow:
$-82.44M
1W Leistung:
+6.53%
1M Leistung:
-2.75%
6M Leistung:
-9.79%
1J Leistung:
-14.17%
1-Tages-Spanne:
$2.00
$2.125
1-Wochen-Bereich:
$2.00
$2.335
52-Wochen-Spanne:
$1.15
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Firmenname
Cassava Sciences Inc
Sektor
Branche
Telefon
512-501-2444
Adresse
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Vergleichen Sie SAVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.12 | 98.07M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-27 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-01-10 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Cassava Sciences Inc Aktie (SAVA) Neueste Nachrichten
Setup Watch: What is Cassava Sciences Inc Equity Warrants book value per shareGold Moves & High Accuracy Swing Trade Signals - baoquankhu1.vn
Cassava Sciences (NASDAQ:SAVA) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Retail Surge: What are the future prospects of Cassava Sciences Inc Equity Warrant2025 Retail Activity & Free Community Consensus Stock Picks - baoquankhu1.vn
The Truth About Cassava Sciences: Wall Street’s Wildcard Stock Everyone Keeps Arguing About - AD HOC NEWS
Aug Retail: What is Cassava Sciences Inc Equity Warrants book value per shareDollar Strength & Verified Trade Idea Suggestions - baoquankhu1.vn
Energy Moves: Is Cassava Sciences Inc backed by strong institutional buyingDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
Cassava Sciences publishes phase 3 Alzheimer’s trial results in JPAD By Investing.com - Investing.com Nigeria
RSI Check: How Cassava Sciences Inc stock trades during market volatilityEarnings Performance Report & Smart Swing Trading Alerts - Bộ Nội Vụ
Cassava Sciences publishes phase 3 Alzheimer’s trial results in JPAD - Investing.com
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease - Yahoo Finance
Alzheimer’s drug trial data reveal blood test limits and safety clues - Stock Titan
Will Cassava Sciences Inc. stock benefit from sector rotationMarket Trend Summary & Smart Money Movement Alerts - ulpravda.ru
What valuation multiples suggest for Cassava Sciences Inc. Equity Warrant stockJuly 2025 Summary & AI Based Buy and Sell Signals - ulpravda.ru
Why Cassava Sciences Inc. Equity Warrant stock remains a top recommendationJuly 2025 Weekly Recap & High Return Trade Guides - ulpravda.ru
How Cassava Sciences Inc. (PX91) stock reacts to weak economyMarket Volume Report & Verified Momentum Watchlists - Улправда
Why Cassava Sciences Inc. (PX91) stock is a must watch tickerWeekly Trend Summary & Trade Opportunity Analysis Reports - Улправда
Signal Recap: Why Cassava Sciences Inc. Equity Warrant stock appeals to analystsJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
Trend Review: What valuation ratios show for Cassava Sciences Inc. (PX91) stockWeekly Profit Report & Safe Entry Momentum Stock Tips - Улправда
Is Cassava Sciences Inc. stock a dividend growth opportunity - ulpravda.ru
How Cassava Sciences Inc. stock responds to policy changesJuly 2025 Trends & Reliable Price Breakout Alerts - Улправда
Published on: 2026-01-09 03:02:15 - Улправда
Does Cassava Sciences Inc. Equity Warrant stock trade at a discount to peers2025 Market Sentiment & Free Verified High Yield Trade Plans - Улправда
Why Cassava Sciences Inc. Equity Warrant stock appeals to analystsMarket Trend Report & Technical Pattern Based Signals - Улправда
Why Cassava Sciences Inc. Equity Warrant stock is in analyst buy zoneJuly 2025 Reactions & Entry Point Confirmation Signals - Улправда
Investors Buy Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA) - MarketBeat
2026 world cup star players odds: Why Cassava Sciences Inc. Equity Warrant stock remains undervalued2026 world cup usa national team round of 16 playmakers counter attacking expert forecast expert opinion - Улправда
Sector Leaders Rotate Capital Into VCU Data Management LimitedTop Performing Stocks & Free Significant Capital Appreciation - Early Times
Aug Reactions: Will Cassava Sciences Inc stock reach all time highs in 2025Market Sentiment Review & Low Volatility Stock Suggestions - moha.gov.vn
Multi Factor Analysis Ranks Ekansh Concepts Limited as Strong BuyStock Price Targets & Register for the Next Free Workshop - earlytimes.in
Quarterly Earnings: Will Cassava Sciences Inc stock see insider buyingInsider Selling & Weekly Watchlist for Hot Stocks - moha.gov.vn
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve
Cassava Sciences settles securities class action for $31.25 million By Investing.com - Investing.com Australia
Cassava Sciences agrees to settle long-running investor lawsuit - The Business Journals
Cassava Sciences agrees to $31.25 million settlement in securities class action By Investing.com - Investing.com Nigeria
Cassava Sciences agrees to $31.25 million settlement in securities class action - Investing.com
Cassava Sciences Agrees to Pay $31.25 Million to Settle Securities Class Action - marketscreener.com
[8-K] CASSAVA SCIENCES INC Reports Material Event | SAVA SEC FilingForm 8-K - Stock Titan
Cassava settles securities class action suit (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences settles securities class action for $31.25 million - Investing.com
Cassava Sciences, Inc. Reaches $31.25 Million Settlement in Consolidated Securities Class Action Litigation - Quiver Quantitative
Cassava announces agreement to settle securities class action litigation - marketscreener.com
Cassava Announces Agreement to Settle Securities Class Action Litigation - GlobeNewswire
Cassava Sciences Shares Plunge After FDA Intervention - AD HOC NEWS
Published on: 2025-12-22 08:32:25 - Улправда
Can Cassava Sciences Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - Улправда
Why Cassava Sciences Inc. Equity Warrant stock appeals to dividend seekersWeekly Earnings Recap & Reliable Price Breakout Alerts - Улправда
Cassava Sciences stock falls after FDA places clinical trial on hold - Investing.com Australia
Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9%What's Next? - MarketBeat
Cassava Sciences stock on track for worst day in about 9 months — what’s driving today’s selloff? - MSN
Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff? - Asianet Newsable
FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold - Benzinga
Finanzdaten der Cassava Sciences Inc-Aktie (SAVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):